Piper Sandler Maintains Overweight on Teva Pharmaceutical Indus, Raises Price Target to $56

Benzinga · 2d ago
Piper Sandler analyst David Amsellem maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Overweight and raises the price target from $44 to $56.